Issue link: http://www.e-digitaleditions.com/i/571156
Tablets made from the blends that included the API exhibited significantly less tensile strength than those made from a similarly lubricated placebo blend. As shown in Figure 2, the placebo with 0.5 percent magnesium stearate achieved a tensile strength of 3,230 kilopascals (kPa) at 300 MPa main compaction pressure; the API blend with 0.5 per- cent magnesium stearate achieved a tensile strength of only 1,780 kPa at 325 MPa main compaction pressure, a decrease in tablet strength of more than a 45 percent. The relative difference between the formulations' strengths decreases to approximately 25 percent at around 100 MPa. It can also been seen that the active blend is near its maxi- mum tensile strength at 325 MPa because the curve becomes increasingly horizontal. Lubrication sensitivity. The amount of magnesium stearate in the formulation had a small but noticeable impact on tablet strength. Decreasing the lubricant in the placebo blend to 0.25 percent resulted in an approximately 6 percent increase in tensile strength. As shown in Figure 3, ejection forces for both blends drop off sharply, with the 0.5 percent blend dropping off sooner. This is the telltale sign of over-lubrication, which occurs when excess lubri- cant is forced from the compact and coats the die walls. In this case, reducing the amount of lubricant would increase tensile strength and decrease dissolution times without causing ejection forces or tooling wear to increase signifi- cantly. Figure 3 also shows a slight decrease in ejection forces at the highest compaction pressures for blends con- taining API, suggesting that they might benefit from a slight reduction in lubricant level to 0.40 or 0.45 percent. All formulations in the compaction-profile and lubrica- tion-sensitivity studies exhibited very low ejection forces. The API-containing blends showed higher ejection forces than the placebos, but ejection forces remained less than 200 newtons for all tablet weights and compaction levels. This is impressive given that the formulation contains 30 percent ibuprofen and almost 35 percent lactose, both of which are known to induce high ejection forces. The co- processing of HPMC with lactose monohydrate has clearly mitigated one of the negative characteristics of lactose (high ejection forces) while preserving its effectiveness as a binder. Strain rate. Brittle materials fracture very quickly when they deform, but materials that deform plastically need more time to assume the shape they're forced into. As a result, brittle materials are relatively unaffected by the rate at which compaction occurs, and plastic materials form weaker compacts at higher production speeds. Lactose and ibuprofen exhibit brittle properties, while HPMC deforms plastically. This raises the question of which behavior will dominate in a blend of these materials. Strain-rate studies can answer this question by compar- ing the strength of tablets produced at varying press speeds. Figure 4 shows that the blend used in this study is strain- rate sensitive and the decrease in the tensile strength of the tablets is characteristic of plastically deforming materials. The figure also shows that the trend levels off after the tan- gential velocity reaches 400 millimeters per second. In some blends, tensile strength remains steady, while in oth- Figure 2 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 Compaction curves of placebo and active tablets (total weight 500 milligrams) 3,400 3,300 3,200 3,100 3,000 2,900 2,800 2,700 2,600 2,500 2,400 2,300 2,200 2,100 2,000 1,900 1,800 1,700 1,600 1,500 1,400 1,300 1,200 1,100 1,000 900 800 700 600 500 400 300 200 500 mg blend Retalac (0.25) Retalac (0.5) Main compression (MPa) Tensile strength (KPa) Tablets & Capsules September 2015 17

